A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

ABSTRACT: Human cytomegalovirus (HCMV) is the most common infection causing poor outcomes among transplant recipients. Maternal infection and transplacental transmission are major causes of permanent birth defects. Although no active vaccines to prevent HCMV infection have been approved, passive immunization with HCMV-specific immunoglobulin has shown promise in the treatment of both transplant and congenital indications. Antibodies targeting the viral glycoprotein B (gB) surface protein are known to neutralize HCMV infectivity, with high-affinity binding being a desirable trait, both to compete with low-affinity antibodies that promote the transmission of virus across the placenta and to displace nonneutralizing antibodies binding nearby epitopes. Using a miniaturized screening technology to charac

SUBMITTER: Kauvar LM 

PROVIDER: S-EPMC4325823 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature